Omalizumab biosimilar - Teva Pharmaceutical Industries
Alternative Names: TEV-45779Latest Information Update: 19 Jun 2024
At a glance
- Originator Teva Pharmaceutical Industries
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic urticaria
Most Recent Events
- 05 Apr 2024 Teva Pharmaceuticals completes a phase III trial in Chronic-urticaria (Treatment-experienced) in USA, Slovakia, Czech Republic, Poland, Greece and Bulgaria (SC) (NCT04976192) (EudraCT2021-001796-17)
- 30 Aug 2021 Phase-III clinical trials in Chronic-urticaria (Treatment-experienced) in Slovakia, Czech Republic, Poland, Greece, Bulgaria (SC) (NCT04976192) (EudraCT2021-001796-17)
- 30 Aug 2021 Phase-III clinical trials in Chronic-urticaria in USA (SC) (NCT04976192)